11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Updated treatment algorithm of pulmonary arterial hypertension.

      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14
      Journal of the American College of Cardiology
      Elsevier BV
      6-min walk distance, 6MWD, APAH, BAS, CCB, ERA, PAH, PVR, RCT, WHO-FC, World Health Organization Functional Class, associated pulmonary arterial hypertension, balloon atrial septostomy, calcium channel blocker, endothelin receptor antagonist, endothelin receptor antagonists, guanylate cyclase stimulators, hypertension, pulmonary, lung transplantation, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary, pulmonary arterial hypertension, pulmonary vascular resistance, randomized controlled trials

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes different types of recommendations with varying degrees of scientific evidence. In addition, the algorithm is required to be comprehensive but not too complex, informative yet simple and straightforward. The type of information in the treatment algorithm are heterogeneous including clinical, hemodynamic, medical, interventional, pharmacological and regulatory recommendations. Stakeholders (or users) including physicians from various specialties and with variable expertise in PAH, nurses, patients and patients' associations, healthcare providers, regulatory agencies and industry are often interested in the PAH treatment algorithm for different reasons. These are the considerable challenges faced when proposing appropriate updates to the current evidence-based treatment algorithm.The current treatment algorithm may be divided into 3 main areas: 1) general measures, supportive therapy, referral strategy, acute vasoreactivity testing and chronic treatment with calcium channel blockers; 2) initial therapy with approved PAH drugs; and 3) clinical response to the initial therapy, combination therapy, balloon atrial septostomy, and lung transplantation. All three sections will be revisited highlighting information newly available in the past 5 years and proposing updates where appropriate. The European Society of Cardiology grades of recommendation and levels of evidence will be adopted to rank the proposed treatments.

          Related collections

          Author and article information

          Journal
          J Am Coll Cardiol
          Journal of the American College of Cardiology
          Elsevier BV
          1558-3597
          0735-1097
          Dec 24 2013
          : 62
          : 25 Suppl
          Affiliations
          [1 ] Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy. Electronic address: nazzareno.galie@unibo.it.
          [2 ] Institute of Cellular Medicine Newcastle University and The Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom.
          [3 ] Baylor College of Medicine, Houston, Texas.
          [4 ] Michigan State University, College of Human Medicine, Grand Rapids, Michigan.
          [5 ] Division of Respirology, University of Toronto, Toronto, Canada.
          [6 ] Fu Wai Hospital & National Center for Cardiovascular Disease Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China.
          [7 ] Department of Thoracic Surgery, Medical University Vienna/Vienna General Hospital, Vienna, Austria.
          [8 ] Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
          [9 ] Cardiovascular Medicine, The University of Michigan, Ann Arbor, Michigan.
          [10 ] Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts.
          [11 ] Medical School, University of California, San Diego, La Jolla, California.
          [12 ] Clinical Research, National Institute of Cardiology of Mexico, Mexico City, Mexico.
          [13 ] Max Planck Institute for Heart and Lung Research, Universities of Giessen and Marburg Lung Center, Giessen/Bad Nauheim, Germany.
          [14 ] Heart Transplant Unit, St Vincent's Hospital, Sydney, Australia.
          Article
          S0735-1097(13)05874-9
          10.1016/j.jacc.2013.10.031
          24355643
          efa392a1-218a-4efd-834d-11f74933ef93
          Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
          History

          6-min walk distance,6MWD,APAH,BAS,CCB,ERA,PAH,PVR,RCT,WHO-FC,World Health Organization Functional Class,associated pulmonary arterial hypertension,balloon atrial septostomy,calcium channel blocker,endothelin receptor antagonist,endothelin receptor antagonists,guanylate cyclase stimulators,hypertension, pulmonary,lung transplantation,phosphodiesterase type-5 inhibitors,prostanoids,pulmonary,pulmonary arterial hypertension,pulmonary vascular resistance,randomized controlled trials

          Comments

          Comment on this article

          scite_

          Similar content144

          Cited by165